85,642 Shares in Tango Therapeutics, Inc. $TNGX Bought by Legal & General Group Plc

Legal & General Group Plc bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 85,642 shares of the company’s stock, valued at approximately $2,677,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TNGX. Allworth Financial LP bought a new stake in shares of Tango Therapeutics in the second quarter worth about $35,000. Global Retirement Partners LLC bought a new position in shares of Tango Therapeutics during the 2nd quarter valued at about $122,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Tango Therapeutics during the 4th quarter valued at about $40,000. State of Wyoming acquired a new position in shares of Tango Therapeutics in the 1st quarter valued at approximately $128,000. Finally, Russell Investments Group Ltd. grew its position in shares of Tango Therapeutics by 461.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,729 shares of the company’s stock valued at $65,000 after purchasing an additional 6,352 shares during the period. 78.99% of the stock is owned by institutional investors and hedge funds.

Tango Therapeutics Trading Down 1.1%

Shares of TNGX opened at $22.52 on Friday. The company’s fifty day simple moving average is $27.05 and its 200 day simple moving average is $23.48. Tango Therapeutics, Inc. has a 1-year low of $6.25 and a 1-year high of $34.39. The company has a market cap of $3.80 billion, a price-to-earnings ratio of -26.49 and a beta of 1.12.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). As a group, research analysts forecast that Tango Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Buying and Selling

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total transaction of $798,930.00. Following the transaction, the insider owned 115,743 shares of the company’s stock, valued at $3,424,835.37. The trade was a 18.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Weiss Ratings upgraded shares of Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wedbush upped their price target on shares of Tango Therapeutics from $19.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Guggenheim increased their price objective on shares of Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Jefferies Financial Group upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating and raised their price objective for the stock from $27.00 to $60.00 in a report on Thursday, June 25th. Finally, Wolfe Research set a $35.00 price objective on shares of Tango Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 8th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.46.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.